ChemicalBook >> CAS DataBase List >>LY2801653

LY2801653

CAS No.
1206799-15-6
Chemical Name:
LY2801653
Synonyms
CS-685;NSC32624;LY2801653;NSC 32624;NSC-32624;Merestinib;MET inhibitor;LY2801653(Merestinib);Merestinib(LY 2801653);Merestinib, 10 mM in DMSO
CBNumber:
CB92650875
Molecular Formula:
C30H22F2N6O3
Molecular Weight:
552.53
MDL Number:
MFCD23160048
MOL File:
1206799-15-6.mol
Last updated:2025-12-03 18:03:33
Product description Number Pack Size Price
LY2801653 ≥98% 25978 1mg $62
LY2801653 ≥98% 25978 5mg $180
LY2801653 ≥98% 25978 10mg $330
LY2801653 ≥98% 25978 50mg $893
LY2801653 A3573 100mg $900
More product size

LY2801653 Properties

Boiling point 795.3±60.0 °C(Predicted)
Density 1.42±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility ≥27.65 mg/mL in DMSO; insoluble in H2O; ≥5.02 mg/mL in EtOH with gentle warming and ultrasonic
form solid
pka 10.83±0.70(Predicted)
color White to yellow
InChIKey QHADVLVFMKEIIP-UHFFFAOYSA-N
SMILES C1(=O)N(C2=CC=C(F)C=C2)C(C)=CC=C1C(NC1=CC=C(OC2C(C3=CNN=C3)=CC3=C(C=2)C=NN3C)C(F)=C1)=O
FDA UNII 5OGS5K699E
NCI Drug Dictionary merestinib

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS07,GHS08
Signal word  Danger
Hazard statements  H360-H302-H351-H372
Precautionary statements  P260-P264-P270-P314-P501-P264-P270-P301+P312-P330-P501-P201-P202-P281-P308+P313-P405-P501
NFPA 704
0
2 0

LY2801653 price More Price(22)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 25978 LY2801653 ≥98% 1206799-15-6 1mg $62 2024-03-01 Buy
Cayman Chemical 25978 LY2801653 ≥98% 1206799-15-6 5mg $180 2024-03-01 Buy
Cayman Chemical 25978 LY2801653 ≥98% 1206799-15-6 10mg $330 2024-03-01 Buy
Cayman Chemical 25978 LY2801653 ≥98% 1206799-15-6 50mg $893 2024-03-01 Buy
ApexBio Technology A3573 LY2801653 1206799-15-6 100mg $900 2021-12-16 Buy
Product number Packaging Price Buy
25978 1mg $62 Buy
25978 5mg $180 Buy
25978 10mg $330 Buy
25978 50mg $893 Buy
A3573 100mg $900 Buy

LY2801653 Chemical Properties,Uses,Production

Description

LY2801653 is an orally bioavailable MET kinase inhibitor (Ki = 2 nM). It also inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively, in a cell-based assay). It inhibits MET autophosphorylation stimulated by hepatocyte growth factor (HGF) in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM). LY2801653 (0.01-10 μM) completely blocks cell scattering induced by HGF in DU145 cells. It reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models when administered at doses of 4 and 12 mg/kg.

Description

MET is a tyrosine kinase that leads to downstream activation of several pathways including RAS and MAPK.?As a result, it is quite possible that MET inhibition can be active in RAS mutant tumors and maybe associated with EGFR resistance in NSCLC.?Two MET inhibitors, tivantinib and onartuzumab, have been examined in KRAS mutant NSCLC with others in clinical trials at this time.

Uses

LY2801653(Merestinib), a c-MET inhibitor developed by Lilly, has shown promising therapeutic effects in many solid tumors by targeting c-MET/HGFR and is used in clinical trials to treat a variety of oncolytic indications.

Mechanism of action

LY2801653(Merestinib) inhibited phosphorylation of eIF4E in MV4-11, MM6 and AML-PT cells, blocked the cell cycle in the G0/G1 phase by decreasing the expression of cyclin A2 and cyclin B1, arrested colony formation, induced apoptosis in MV4-11 cells and exhibited antileukemic properties in vivo.

Clinical Use

Preclinical testing also has shown merestinib to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and NTRK1/2/3.

target

c-MET

References

[1] yan s b et al. , ly2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against met, mst1r, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. invest new drugs. 2012, 31: 833-844.

LY2801653 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 144)Suppliers
Supplier Tel Email Country ProdList Advantage
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 33024 60
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 965 58
career henan chemical co
+86-0371-86658258 +8613203830695 factory@coreychem.com China 29798 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-81139210 +86-18192627656 1059@dideu.com China 3588 58
Suzhou Ryan Pharmachem Technology Co.,Ltd.
+86-512-68780025 sales@ryanchem.com China 169 58
TargetMol Chemicals Inc.
+1-781-999-5354; +17819995354 marketing@targetmol.com United States 32435 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226 sales@hzclap.com CHINA 6312 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 sales@sarms4muscle.com China 10473 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6391 58
HANGZHOU LEAP CHEM CO., LTD.
+86-571-87711850 market18@leapchem.com China 24727 58

View Lastest Price from LY2801653 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Merestinib pictures 2025-12-05 Merestinib
1206799-15-6
US $107.00-267.00 / mg 99.24% 10g TargetMol Chemicals Inc.
Merestinib pictures 2022-04-29 Merestinib
1206799-15-6
US $1.00-100.00 / g 1g 99.8%min 25Kg Shaanxi Dideu Medichem Co. Ltd
LY2801653 pictures 2019-12-26 LY2801653
1206799-15-6
US $1.00 / KG 1KG 97%-99.9% 100kg Career Henan Chemical Co
  • Merestinib pictures
  • Merestinib
    1206799-15-6
  • US $107.00-267.00 / mg
  • 99.24%
  • TargetMol Chemicals Inc.
  • Merestinib pictures
  • Merestinib
    1206799-15-6
  • US $1.00-100.00 / g
  • 99.8%min
  • Shaanxi Dideu Medichem Co. Ltd
  • LY2801653 pictures
  • LY2801653
    1206799-15-6
  • US $1.00 / KG
  • 97%-99.9%
  • Career Henan Chemical Co

LY2801653 Spectrum

LY2801653 N-(3-fluoro-4-((1-Methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-Methyl-2-oxo-1,2-dihydropyridine-3-carboxaMide N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarboxamide Merestinib LY2801653(Merestinib) N-(3-Fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6- Merestinib(LY 2801653) N-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide CS-685 MET inhibitor MET INHIBITOR; LY2801653; LY-2801653; LY 2801653; MERESTINIB 3-Pyridinecarboxamide, N-[3-fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo- NSC 32624 NSC32624 NSC-32624 Merestinib, 10 mM in DMSO N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3 Merestinib(LY 2801653), 98%min Merestinib (LY2801653) ,S7014 1206799-15-6 C30H22F2N6O3 API